TGFβ1-induced hedgehog signaling suppresses the immune response of brain microvascular endothelial cells elicited by meningitic Escherichia coli.
Brain microvascular endothelial cells
Escherichia coli
Hedgehog signaling
Neuroinflammation
SAG
TGFβ1
miR-155
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
15 02 2024
15 02 2024
Historique:
received:
01
09
2023
accepted:
03
11
2023
medline:
19
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Meningitic Escherichia coli (E. coli) is the major etiological agent of bacterial meningitis, a life-threatening infectious disease with severe neurological sequelae and high mortality. The major cause of central nervous system (CNS) damage and sequelae is the bacterial-induced inflammatory storm, where the immune response of the blood-brain barrier (BBB) is crucial. Western blot, real-time PCR, enzyme-linked immunosorbent assay, immunofluorescence, and dual-luciferase reporter assay were used to investigate the suppressor role of transforming growth factor beta 1 (TGFβ1) in the immune response of brain microvascular endothelial cells elicited by meningitic E. coli. In this work, we showed that exogenous TGFβ1 and induced noncanonical Hedgehog (HH) signaling suppressed the endothelial immune response to meningitic E. coli infection via upregulation of intracellular miR-155. Consequently, the increased miR-155 suppressed ERK1/2 activation by negatively regulating KRAS, thereby decreasing IL-6, MIP-2, and E-selectin expression. In addition, the exogenous HH signaling agonist SAG demonstrated promising protection against meningitic E. coli-induced neuroinflammation. Our work revealed the effect of TGFβ1 antagonism on E. coli-induced BBB immune response and suggested that activation of HH signaling may be a potential protective strategy for future bacterial meningitis therapy. Video Abstract.
Sections du résumé
BACKGROUND
Meningitic Escherichia coli (E. coli) is the major etiological agent of bacterial meningitis, a life-threatening infectious disease with severe neurological sequelae and high mortality. The major cause of central nervous system (CNS) damage and sequelae is the bacterial-induced inflammatory storm, where the immune response of the blood-brain barrier (BBB) is crucial.
METHODS
Western blot, real-time PCR, enzyme-linked immunosorbent assay, immunofluorescence, and dual-luciferase reporter assay were used to investigate the suppressor role of transforming growth factor beta 1 (TGFβ1) in the immune response of brain microvascular endothelial cells elicited by meningitic E. coli.
RESULT
In this work, we showed that exogenous TGFβ1 and induced noncanonical Hedgehog (HH) signaling suppressed the endothelial immune response to meningitic E. coli infection via upregulation of intracellular miR-155. Consequently, the increased miR-155 suppressed ERK1/2 activation by negatively regulating KRAS, thereby decreasing IL-6, MIP-2, and E-selectin expression. In addition, the exogenous HH signaling agonist SAG demonstrated promising protection against meningitic E. coli-induced neuroinflammation.
CONCLUSION
Our work revealed the effect of TGFβ1 antagonism on E. coli-induced BBB immune response and suggested that activation of HH signaling may be a potential protective strategy for future bacterial meningitis therapy. Video Abstract.
Identifiants
pubmed: 38360663
doi: 10.1186/s12964-023-01383-y
pii: 10.1186/s12964-023-01383-y
pmc: PMC10868028
doi:
Substances chimiques
Hedgehog Proteins
0
MicroRNAs
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2024. The Author(s).
Références
Eur J Neurosci. 1996 Sep;8(9):1803-11
pubmed: 8921271
J Virol. 2016 Apr 14;90(9):4780-4795
pubmed: 26937036
Glia. 2014 Dec;62(12):2044-60
pubmed: 25043492
Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):22-9
pubmed: 19057183
CNS Neurosci Ther. 2012 Nov;18(11):903-8
pubmed: 22978829
Gene. 2013 Dec 10;532(1):1-12
pubmed: 23246696
J Clin Invest. 2019 Jul 2;129(8):3153-3170
pubmed: 31264977
J Clin Invest. 2019 Dec 2;129(12):5151-5162
pubmed: 31638600
J Neuroinflammation. 2018 Oct 19;15(1):291
pubmed: 30340642
J Cell Biol. 2001 Oct 1;155(1):133-43
pubmed: 11581290
J Neuropathol Exp Neurol. 2003 Jun;62(6):593-604
pubmed: 12834104
J Hematol Oncol. 2020 Aug 17;13(1):113
pubmed: 32807225
Nat Commun. 2020 Jan 10;11(1):214
pubmed: 31924781
Front Immunol. 2019 Jan 29;9:3100
pubmed: 30761156
Oncotarget. 2016 Jul 5;7(27):42683-42697
pubmed: 26967056
Oncotarget. 2016 Sep 27;7(39):63839-63855
pubmed: 27588479
Nat Rev Immunol. 2015 Nov;15(11):692-704
pubmed: 26471775
Int J Mol Sci. 2023 Feb 02;24(3):
pubmed: 36769171
J Neuroinflammation. 2023 Jul 23;20(1):173
pubmed: 37481642
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15107-12
pubmed: 14645708
J Neuroinflammation. 2014 May 29;11:97
pubmed: 24885259
EcoSal Plus. 2016 May;7(1):
pubmed: 27223820
J Neuroinflammation. 2019 May 15;16(1):101
pubmed: 31092253
Phytomedicine. 2017 Feb 15;25:8-14
pubmed: 28190474
Pharmacol Rev. 2018 Apr;70(2):278-314
pubmed: 29496890
F1000Res. 2017 Jan 27;6:
pubmed: 28184287
Trends Mol Med. 2003 Jun;9(6):263-8
pubmed: 12829015
FEBS J. 2015 Nov;282(21):4067-79
pubmed: 26277326
Brain Sci. 2021 Jan 08;11(1):
pubmed: 33430164
PLoS Pathog. 2016 Oct 6;12(10):e1005926
pubmed: 27711202
Cell Commun Signal. 2014 Oct 14;12:65
pubmed: 25311416
Eur J Pharmacol. 2016 Jan 15;771:18-28
pubmed: 26683637
PLoS Pathog. 2012;8(10):e1002947
pubmed: 23055927
J Neuroinflammation. 2022 Jun 15;19(1):149
pubmed: 35705998
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29795022
Mol Brain. 2021 Jul 19;14(1):116
pubmed: 34281571
Nat Rev Neurosci. 2003 May;4(5):376-85
pubmed: 12728265
Mol Biotechnol. 2005 May;30(1):57-70
pubmed: 15805577
Lancet. 2017 Dec 17;388(10063):3036-3047
pubmed: 27265346
Int J Biol Sci. 2012;8(2):228-35
pubmed: 22253566
J Biol Chem. 2013 Dec 13;288(50):35982-96
pubmed: 24165132
Cell Mol Neurobiol. 2017 May;37(4):619-633
pubmed: 27380043
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Trends Pharmacol Sci. 2012 Jul;33(7):382-93
pubmed: 22613783
Am J Pathol. 2006 Apr;168(4):1200-9
pubmed: 16565495
EMBO J. 2004 Apr 21;23(8):1770-81
pubmed: 15057277
J Neuroimmunol. 2019 Jan 15;326:38-44
pubmed: 30472304
Cell Mol Immunol. 2009 Oct;6(5):343-52
pubmed: 19887047